| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Reproductive System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Reproductive System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Reproductive System |
Recent Updates
Recently added Catalysts
Dare Bioscience, Inc.$2.02
-0.06 (-2.9%)
D 27Pipeline Score Overvalued Pharma · Commercial
Market Cap
35.50 M
EPS
-1.04
P/E Ratio
-
Value Trade
464.47 K
SEC Financials
Q1 2026Dilution Risk
Revenue
152.46 K
R&D Expenses
660.46 K
Operating CF
-5.52 M
Total Assets
27.83 M
Total Liabilities
27.09 M
Equity
734.45 K
D/E Ratio
12,345
8.72 %
Week
-2.87 %
1 Month
41.92 %
3 Month
44.51 %
6 Month
-85.15 %
5 Year
-99.72 %
All Time
Cash Data
Cash Position
18.52 M
Monthly Burn
1.84 M
Runway
8.4 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
49.13 K
52 Week Range
1.27 - 9.19
% held by Insiders
9.06 %
% held by Institutions
6.84 %
Enterprise Value
24.17 M
Total Shares
14.97 M
Short %
5.26 %
Float Shares
13.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dare Bioscience, Inc.
337Total events
9Upcoming
103Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 9
2027
T2Product Launch
DARE to RECLAIM targeted to be available for prescription fulfillment in early 2027
TBD
T1NDA Submission
Daré plans to seek FDA approval of proprietary sildenafil cream formulation in the future
TBD
T2Timing Guidance
Daré to continue activities to seek FDA approval of proprietary sildenafil cream formulation
TBD
T1Partnership / License
Exploring strategic partnering for DARE-IDDS platform beyond reproductive health
Event history 328
May 18, 2026
▲Trial InitiationDARE-HPVTrial
Initiation of Phase 2 clinical study of DARE-HPV
persistent high-risk HPV infectionsource ↗
May 14, 2026
Q2 2026
▲Product LaunchPost-Market
Flora Sync LF5 expected to become commercially available through DARE Health Hub
vaginal microbiome balancesource ↗
Mar 26, 2026
◆Quarterly UpdateCorporate
Full Year 2025 Financial Results and Company Update Conference Call
Mar 26, 2026
▲Product LaunchPost-Market
Commercial launch of DARE to PLAY Sildenafil Cream as 503B compounded product
female sexual arousal disordersource ↗
Mar 23, 2026
▲Product LaunchPost-Market
DARE to PLAY™ Sildenafil Cream available as Section 503B compounded product
female sexual arousalsource ↗
Mar 12, 2026
▲IND ClearanceDARE-HPVIND
FDA clearance of IND for DARE-HPV
high-risk human papillomavirus (HPV) infectionsource ↗
Feb 23, 2026
▲IND ClearanceDARE-HPVIND
FDA cleared IND for DARE-HPV Phase 2 study
persistent high-risk HPV infectionsource ↗
Feb 11, 2026
▲Product LaunchPost-Market
Telehealth consultations for DARE to PLAY™ Sildenafil Cream now available nationwide
female sexual arousalsource ↗
Feb 2026
◆Partnership / LicenseOvapreneCorporate
Bayer terminates license agreement for Ovaprene; rights to return to Dare
contraceptionsource ↗
Feb 2026
▲IND ClearanceDARE-HPVIND
FDA cleared IND application for DARE-HPV
persistent high-risk HPV infectionsource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $7M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankDare Bioscience, Inc. faces pipeline headwinds (27/100), with $331M risk-adjusted pipeline value, led by Lopinavir / ritonavir in Human Papilloma Virus (HPV) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lopinavir / ritonavir Small molecule | Human Papilloma Virus (HPV) | Phase 2 | NCT07601074 | 21% | $171M | NOT YET_RECRUITING | 118 | VERY_FAST | C (59) | Dec 1, 2027 | - | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ovaprene | hormone-free contraceptive | Phase 3 | 2025-12-01 | the rate of pregnancy in women treated in the study at the time of the interim analysis was consistent with the company's expectations based on the results of the pre-pivotal postcoital test clinical study of Ovaprene Read More | Dar Bioscience Announces Return of Rights to Ovaprene ; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization Read More | |
Ovaprene | hormone-free contraceptive | Phase 3 | 2025-12-01 | the rate of pregnancy in women treated in the study at the time of the interim analysis was consistent with the company's expectations based on the results of the pre-pivotal postcoital test clinical study of Ovaprene Read More | Dar Bioscience Announces Return of Rights to Ovaprene ; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization Read More | |
Ovaprene | hormone-free contraceptive | Phase 3 | 2025-12-01 | the rate of pregnancy in women treated in the study at the time of the interim analysis was consistent with the company's expectations based on the results of the pre-pivotal postcoital test clinical study of Ovaprene Read More | Dar Bioscience Announces Return of Rights to Ovaprene ; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DARE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DARE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DAREPress Release: Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Daré Bioscience has launched Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance and enhancing vaginal comfort. This product represents the company's first direct-to-consumer offering, marking a significant shift towards revenue generation. Flora Sync LF5 is available without a prescription and is backed by clinical research demonstrating its effectiveness.
Read more →DAREThe Vaginal Probiotic Built on Real Science, Flora Sync LF5
Daré Bioscience has launched Flora Sync LF5, a vaginal probiotic uniquely isolated from the vaginal microbiome of healthy women. Backed by a randomized controlled trial, the product has shown significant efficacy in restoring vaginal microbiome balance. This probiotic aims to address the credibility issues in the women's wellness market by providing scientifically validated health solutions.
Read more →DAREPress Release: Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
Daré Bioscience announced the upcoming launch of Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance. CEO Sabrina Martucci Johnson highlighted its significance as the company's first consumer health product, which is expected to generate direct revenue. The product aligns with Daré's mission to address women's health needs through innovative solutions.
Read more →DAREPress Release: Daré Bioscience to Showcase Leadership in Women’s Health Innovation at BIO International Convention 2026
Daré Bioscience will participate in the BIO International Convention 2026, showcasing its commitment to women's health innovation. CEO Sabrina Martucci Johnson will deliver multiple presentations, discussing the company's corporate strategy and addressing gaps in women's healthcare. The event serves as a platform for collaboration with industry leaders and investors.
Read more →DAREPress Release: Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
Daré Bioscience announced the upcoming launch of Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance and enhancing vaginal comfort. This launch signifies a pivotal transition for the company as it prepares to generate its first direct consumer product revenue. Flora Sync LF5 is designed specifically for vaginal health and will be available without a prescription, priced at $49 per box.
Read more →DAREDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Daré Bioscience has announced the receipt of a $1 million NIH funding award, bringing the total to $2 million for its investigational treatment DARE-HPV. This funding supports the Phase 2 clinical study, which is the first opportunity for women with persistent high-risk HPV infection to access a pharmacologic treatment. The study aims to evaluate the safety and antiviral activity of DARE-HPV in approximately 100 women.
Read more →DARE▼ -7.9%on this news
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
Daré Bioscience, a health biotech company focused on women's health, will host a conference call on May 14, 2026, to discuss its financial results for Q1 2026 and provide company updates. The call will be accessible via phone and webcast, with details available on their investor relations website. Daré aims to bridge the gap in women's health through evidence-based solutions.
Read more →DAREDaré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Daré Bioscience reported its financial results for 2025, highlighting the commercial launch of DARE to PLAY, a topical sildenafil cream for women. The company is advancing a diverse pipeline of women's health solutions, including products for vaginal health and hormone therapy. With significant funding and multiple catalysts on the horizon, Daré aims to address unmet needs in women's health.
Read more →DAREOn National Viagra Day, Women Finally Claim Their Turn:
Daré Bioscience is launching DARE to PLAY™, a topical sildenafil cream designed specifically for women, coinciding with National Viagra Day. This innovative product aims to enhance women's sexual wellness by increasing genital blood flow and improving arousal sensations. The cream is clinically studied and represents a significant advancement in addressing women's sexual health needs, which have historically been underserved.
Read more →DAREDaré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
Daré Bioscience will host a conference call on March 26, 2026, to discuss its financial results for the year ending December 31, 2025. The call will provide updates on the company's progress in women's health solutions. Interested parties can access the call via phone or live webcast, with an archive available afterward.
Read more →DAREDaré Bioscience Participates in Virtual Investor “What This Means” Segment
Daré Bioscience announced that its CEO, Sabrina Martucci Johnson, participated in a Virtual Investor segment discussing the FDA's clearance of the IND for DARE-HPV. This clearance allows the company to proceed with a Phase 2 clinical study aimed at addressing persistent high-risk HPV infections. Johnson highlighted the significance of this milestone for women's health and the potential market opportunities that could arise from positive trial results.
Read more →DAREDaré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Daré Bioscience has received FDA clearance for its IND application for DARE-HPV, a novel treatment aimed at persistent high-risk HPV infection, which is a leading cause of cervical cancer. This approval allows the initiation of a Phase 2 clinical study to evaluate the safety and efficacy of DARE-HPV. The therapy is designed to intervene earlier than current standards of care, potentially transforming the management of HPV infections in women.
Read more →DARETelehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
DARE Bioscience has launched telehealth consultations for its DARE to PLAY™ Sildenafil Cream, the first evidence-based topical arousal cream for women. This innovative product is designed to enhance genital blood flow and arousal sensations, marking a significant advancement in women's sexual health. The company aims to provide women with a convenient way to access this treatment through the DARE Health Hub, with prescriptions expected to be fulfilled soon.
Read more →DARE▲ +7%on this news· ran to +23% by day 3
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
DARE Bioscience has announced the pre-order availability of DARE to PLAY™ Sildenafil Cream, the first evidence-based topical arousal cream for women, through select providers in certain states. The cream is designed to enhance genital blood flow using sildenafil, the same active ingredient found in Viagra, and has been clinically validated to improve arousal sensations. DARE to PLAY™ marks a significant advancement in women's sexual health, addressing a long-standing gap in effective treatments. However, it should be noted that the product is not FDA approved, and its distribution is currently limited to specific regions.
Read more →DARE▼ -9.2%on this news
Dar Bioscience Announces Return of Rights to Ovaprene ; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Dare Bioscience announced the return of all rights to Ovaprene from Bayer HealthCare. This strategic move comes as Bayer terminates their license agreement, allowing Dare to have full control over the investigational hormone-free contraceptive. The Phase 3 clinical program for Ovaprene is ongoing, showing positive interim data regarding its safety and efficacy. The ongoing trial is supported by non-dilutive grant funding, enhancing Dare's position to explore potential partnerships and maximize the asset's value.
Read more →DAREDar Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Po
Dar Bioscience reported its financial results for Q3 2025, highlighting the imminent launch of the DARE to PLAY Sildenafil Cream through the 503B pathway. The company is preparing to commercialize several women's health products over the next two years, with a focus on generating near-term revenue. Additionally, positive interim results from the Phase 3 Ovaprene study support the continued enrollment of participants. Despite rising operational costs, Dar maintains a strong cash position as it advances its multi-pronged strategy in women's health.
Read more →DARE▲ +6.6%on this newsshared move
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health
Daré Bioscience announced the upcoming commercial launch of DARE to PLAY™ Sildenafil Cream, a topical formulation aimed at enhancing women's sexual health. The product, supported by clinical data, will be discussed in a webinar featuring leading clinicians. This marks a significant advancement in women's health solutions, with availability expected later this year.
Read more →DAREDaré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Daré Bioscience, a health biotech company focused on women's health, will hold a conference call on November 13, 2025, to discuss its financial results for Q3 2025 and provide company updates. The call will be accessible via phone and webcast, with an archive available until November 27, 2025. The company aims to address critical gaps in women's health through evidence-based solutions.
Read more →DAREDaré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Daré Bioscience has announced a contract with the Gates Foundation to receive up to $300,000 for a strategic landscape assessment of organizations involved in contraceptive product development. The funding will help identify potential partners to enhance the global contraceptive innovation ecosystem. This initiative aligns with Daré's mission to improve women's health through advanced science.
Read more →DAREDaré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Daré Bioscience has secured a $4 million installment of non-dilutive funding, raising its total to $41.8 million under a grant to develop its DARE-LARC1 contraceptive device. This funding will aid in nonclinical development and preparation for an IND application. The DARE-IDDS platform shows promise for broader applications in obesity and metabolic disorders.
Read more →DAREDaré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Daré Bioscience has secured up to $499,000 from the Gates Foundation to support research on preeclampsia, a serious pregnancy complication. The funding will enable Daré to provide mentorship and project management for global research projects aimed at preventing and treating this condition. This initiative underscores the company's commitment to addressing significant gaps in women's health.
Read more →DARE▲ +6.3%on this news
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Daré Bioscience reported its financial results for Q2 2025, highlighting a positive interim outcome for the Ovaprene Phase 3 study and plans for the Q4 launch of DARE to PLAY™ Sildenafil Cream. The company is advancing multiple grant-funded programs aimed at addressing unmet needs in women's health. CEO Sabrina Martucci Johnson emphasized the dual-path strategy for near-term revenue and long-term value creation.
Read more →DAREDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
Daré Bioscience and Rosy Wellness have launched a campaign to support the upcoming DARE to PLAY Sildenafil Cream, aimed at addressing women's arousal concerns. The campaign includes educational content and interactive tools to inform women about sexual health. DARE to PLAY is expected to be available by prescription in the fourth quarter of 2025.
Read more →DAREUPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Daré Bioscience announced a webinar on August 6, 2025, to introduce its innovative DARE to PLAY™ sildenafil cream, designed specifically for women. This topical formulation, which contains the same active ingredient as Viagra®, aims to improve female sexual arousal and is expected to be available by prescription in Q4 2025. The event will feature prominent experts in sexual health and provide insights into this groundbreaking product.
Read more →DARE▲ +22.9%on this news
Positive Interim Phase 3 Results Highlight Potential of Ovaprene , Novel Hormone-Free Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Co
Dar Bioscience, Inc. announced positive interim results from its Phase 3 trial of Ovaprene, a hormone-free monthly intravaginal contraceptive. The independent Data Safety Monitoring Board recommended the study continue without modification, reflecting favorable safety and efficacy results. While the interim findings show a pregnancy rate consistent with expectations, some participants reported discontinuation due to vaginal odor. Overall, the results support Ovaprene's potential as a significant alternative in contraceptive options for women.
Read more →DAREDar Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update In addition to its proprietary Sildenafil Cream formulation, Dar is taking action to make three other solutions for women available
Dar Bioscience, Inc. (NASDAQ: DARE) has reported its financial results for the first quarter of 2025 while announcing its expanded business strategy aimed at enhancing women's health solutions. The company plans to launch vaginal probiotics and a proprietary hormone therapy, with revenues anticipated to begin in Q4 2025. Dar emphasizes a dual-path commercialization strategy that includes both FDA approval and 503B compounding. CEO Sabrina Martucci Johnson expressed confidence in the company's potential to address unmet needs in women's health.
Read more →DAREDar Bioscience Reports Full Year 2024 Financial Results and Provides Company Update With increasing demand for needed treatments designed for women, Dar is taking action to make its proprietary Sildenafil Cream formulati
Dar Bioscience reported its financial results for 2024 and provided an update on its efforts to address the needs of women's health. The company is set to launch its proprietary Sildenafil Cream formulation via prescription this year, meeting growing demand. Dar anticipates starting revenue and cash flow by the fourth quarter of 2025. The firm is also focusing on expanding its product pipeline and engaging in compounding strategies to expedite market access to its offerings.
Read more →DAREDar Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved
Dar Bioscience has announced its plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating Female Sexual Arousal Disorder (FSAD), which currently has no FDA-approved pharmacological treatments. Collaborating with Strategic Science & Technologies, Dar intends to submit the protocol to the FDA in early 2025 and aims to begin the study by mid-2025. If successful, this could mark the first FDA-approved treatment for FSAD, addressing the distress of approximately 10 million women in the U.S. who suffer from the condition.
Read more →DARE▼ -7%on this news· ran to -17% by day 3
Dar Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene hormone-free mo
Dar Bioscience reported its financial results for Q3 2024 and provided an update on several ongoing development initiatives. The company is progressing with pivotal Phase 3 studies for Ovaprene and Sildenafil Cream, among others, while receiving significant funding through grants. A $10 million award from ARPA-H supports the development of DARE-HPV, and recent grants facilitate further clinical site expansion for ongoing studies. Despite the positive momentum, the company faces potential financial burdens related to the Phase 3 study requirements set by the FDA.
Read more →DAREDar Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change
Dare Bioscience has been awarded a $10 million grant from ARPA-H's Sprint for Women's Health to develop DARE-HPV, a potential first-in-category treatment for HPV-related cervical diseases. This funding aims to address critical health challenges faced by women and support the clinical management of HPV-related issues. DARE-HPV could represent the first FDA-approved pharmaceutical intervention for treating high-grade cervical lesions and HPV infections, potentially transforming women's healthcare.
Read more →DAREDar Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC Provides Dar access to capital at Dar 's discretion with any proceeds available to help fund portfolio ad
Dar Bioscience, Inc. has announced a common stock purchase agreement with Lincoln Park Capital Fund for up to $15 million to support its portfolio advancements. The company plans to use this capital for developing Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder. Previously, funding from Lincoln Park facilitated the FDA approval of XACIATO, illustrating a productive collaborative history. This agreement allows Dar controlled access to the capital based on their discretion over a 24-month period.
Read more →DAREDar Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene hormone-f
Dar Bioscience, Inc. reported its financial results for Q2 2024, highlighting ongoing recruitment for its pivotal Phase 3 study of Ovaprene, a hormone-free contraceptive. The company also made progress toward initiating a Phase 3 study for its Sildenafil Cream, aimed at treating female sexual arousal disorder. Dar secured $22 million in non-dilutive financing and noted a decrease in general and administrative expenses year-over-year. A conference call and webcast are scheduled to provide further updates and review financial outcomes today at 4:30 PM ET.
Read more →DARE▲ +11%on this news
Dar Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Dare Bioscience, Inc. has regained compliance with the Nasdaq minimum bid price requirement, following a closing bid price of $1.00 or greater for ten consecutive sessions. This development is seen as a strengthening of the company's market position. The company is actively enrolling participants in a pivotal Phase 3 trial of Ovaprene, a hormone-free contraceptive, and is moving toward a Phase 3 trial for Sildenafil Cream to treat female sexual arousal disorder. Overall, Dare aims to advance innovative therapies tailored for women's health.
Read more →DARE▼ -14.6%on this news· ran to -30% by day 3
Dar Bioscience Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on
Dar Bioscience, Inc. announced a 1-for-12 reverse stock split of its common stock, effective on July 1, 2024, to comply with Nasdaq's minimum bid price. The split aims to increase the stock price above $1.00 to maintain its listing on the Nasdaq Capital Market. Following the split, approximately 101.1 million shares will reduce to about 8.4 million. This move comes after stockholder approval during the annual meeting on June 5, 2024, and is part of Dar's ongoing strategy to support its financial health and continue advancing women's health products.
Read more →DAREDar Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene hormone-fr
Dar Bioscience has reported its financial results for the first quarter of 2024, highlighting progress on several key programs. The company's pivotal Phase 3 study for the hormone-free contraceptive Ovaprene is currently enrolling participants across the United States. Additionally, Dar is advancing its Sildenafil Cream for female sexual arousal disorder towards a Phase 3 trial after a successful end-of-Phase 2 meeting with the FDA. The company secured $22 million in strategic financing, positioning it well for anticipated milestones in 2024.
Read more →DARE▲ +9.1%on this news
Dar Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts $22 million of non-dilutive capital at close pro
Dar Bioscience, Inc. announced the closure of a $22 million royalty financing transaction with XOMA to support the advancement of its Phase 3 women's health product candidates. This financing allows Dar to focus on developing its investigational products, Ovaprene, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder. The deal is structured to provide Dar with upside-sharing milestone payments as their products achieve market success. Overall, this funding underscores Dar's commitment to enhancing innovative therapies in women's health.
Read more →DARE▼ -10.7%on this news
Dar Bioscience Reports Full Year 2023 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2023 Highlights and Anticipated 2024 Milestones XACIATO (clindamycin phosphate) vagina
Dar Bioscience reported promising financial results for 2023 and outlined key milestones for 2024, highlighting advancements in women's health innovations. The U.S. launch of XACIATO, a treatment for bacterial vaginosis, marks a significant addition to their portfolio. Additionally, the company is advancing with pivotal studies for Ovaprene, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder. The potential for increased FDA collaboration bodes well for the development of these products.
Read more →DAREDare Bioscience Announces Executive Team and Board of Directors Changes SAN DIEGO, JAN. 26, 2024 - Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced changes in company managemen
Dare Bioscience, Inc. announced management changes, including the retirement of Chief Financial Officer Lisa Walters-Hoffert and the resignation of Chief Commercial Officer John Fair. Both executives will assist in a transition period, and the company is reducing its Board of Directors. The restructuring aims to optimize operations and maintain focus on late-stage product candidates, although it raises concerns over potential leadership gaps in the near future.
Read more →DAREDar Bioscience Secures $12 million in Royalty-backed Investment Structure $5 million at closing and up to $7 million of additional committed funding SAN DIEGO, December, 26, 2023 - Dar Bioscience, Inc. (NASDAQ: DARE), a
Dar Bioscience, Inc. announced a royalty-backed financing agreement amounting to $12 million, with $5 million received at closing and up to $7 million available through future tranches. This funding aims to advance their late-stage product candidates, which focus on women's health. The agreement includes a revenue-sharing structure that will revert royalties back to Dar after the investor achieves a 12% internal rate of return. However, potential risks include the implications of revenue sharing on cash flows and the unpredictability of meeting the targeted returns.
Read more →DAREDare Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-
Dare Bioscience announced positive topline results from its Phase 1 clinical study of DARE-PDM1, an investigational vaginal treatment for primary dysmenorrhea. The study demonstrated that DARE-PDM1 was well-tolerated and effective in reducing pain scores associated with dysmenorrhea when compared to a placebo. The results support continued clinical development, highlighting its potential as a first-in-category product that may extend the duration of pain relief. The vaginal delivery method aims to minimize the risks commonly associated with oral NSAIDs.
Read more →DARE▼ -6.9%on this news
Dar Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO : receipt of $1.8 million trigger
Dar Bioscience, Inc. announced its third-quarter 2023 financial results, highlighting significant progress in multiple projects, including the launch of XACIATO, which triggered a $1.8 million milestone payment. The company is set to commence a pivotal Phase 3 efficacy study for Ovaprene, a non-hormonal contraceptive. Additionally, Dar is preparing for an end-of-Phase 2 meeting with the FDA regarding its Sildenafil Cream, which addresses female sexual arousal disorders. The fourth quarter is anticipated to be busy with multiple key milestones.
Read more →DAREDar Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program Additional Analyses of Phase 2b Data Cond
Dar Bioscience announced further positive results from the Phase 2b RESPOND study of Sildenafil Cream, a treatment for female sexual arousal disorder. The study demonstrated statistically significant improvements in arousal sensation and distress related to sexual dysfunction among participants. With these promising findings, the company aims to advance to a Phase 3 program, potentially addressing a significant unmet need in women's sexual health. The company plans to discuss these results in an upcoming meeting with the FDA.
Read more →DARE▲ +14.3%on this news
Dar Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older
Dar Bioscience announced the first commercial milestone for XACIATO, a vaginal gel approved for treating bacterial vaginosis, triggering a $1.8 million payment under a license agreement with Organon. The company has advanced the product from pivotal clinical trials to FDA approval in under five years. They expect additional future milestone payments of up to $180 million and tiered royalties. Despite this success, there are potential risks regarding payment realizations and reliance on commercialization partners.
Read more →DAREDar Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Dar Bioscience, Inc. has announced a $7 million registered direct offering of its common stock and warrants to purchase additional shares, which will close around September 1, 2023. The offering is expected to be priced at $0.70 per share, with associated warrants exercisable starting six months post-issuance. The proceeds will be utilized for general corporate purposes, including potential clinical trials and research initiatives. This move highlights the company's strategy to advance innovations in women's health while navigating market conditions under Nasdaq regulations.
Read more →DAREDar Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)) : XACIATO First
Dar Bioscience, Inc. (NASDAQ: DARE) reported its financial results for the second quarter of 2023 and highlighted upcoming milestones. Key developments include the commencement of a pivotal Phase 3 study for its contraceptive candidate Ovaprene and the planned commercial launch of XACIATO. Additionally, the company announced positive topline results from an exploratory Phase 2b study of Sildenafil Cream aimed at addressing female sexual dysfunction. The firm holds a robust pipeline with several other products expected to advance in the near future.
Read more →DARE▼ -6.6%on this news
Dar Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Dar to receive $1 mil
Dar Bioscience has provided an update on its activities to support the commercial launch of XACIATO, an FDA-approved vaginal gel indicated for bacterial vaginosis in women aged 12 and older. The company will receive $1 million from Organon in July 2023, along with potential milestone payments totaling up to $181.8 million. Dar has completed the necessary manufacturing validation and anticipates a launch in the U.S. later this year. The positive results from the clinical trial further strengthen confidence in XACIATO's market acceptance.
Read more →DAREDar Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Sildenafil Cream-treated patients showed meaningful improv
Dar Bioscience has announced positive topline results from the exploratory Phase 2b RESPOND study of Sildenafil Cream, 3.6%, for treating female sexual arousal disorder (FSAD). The study demonstrated significant improvements in sexual function among treated patients, suggesting potential therapeutic benefits. Despite being underpowered for full statistical significance, certain endpoints achieved significance and can inform future Phase 3 studies. The company aims to work closely with the FDA to further develop this innovative treatment option for women's sexual health.
Read more →DAREDar Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Di
Dar Bioscience reported its financial results for the first quarter of 2023 and shared updates on upcoming milestones. Key highlights include the anticipated topline data from the Phase 2b clinical study of Sildenafil Cream for Female Sexual Arousal Disorder and the expected commercial launch of XACIATO, the company's first FDA-approved product. The company is actively pursuing 12 development programs across various women's health indications, with significant partnerships in place. However, an increase in general and administrative expenses raises concerns about financial management.
Read more →DAREDar Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2022 Dar Key Portfolio Accomplishments: License Agreement with Organon to Commercial
Dar Bioscience, Inc. reported its financial results for 2022 and outlined recent achievements in its product portfolio. Key highlights include a global license agreement with Organon for the commercialization of XACIATO and positive topline data from Phase 1/2 studies for two candidates. The company received FDA approval for a pivotal study related to its contraceptive product, Ovaprene, and reported a significant increase in funding. While the company faces rising expenses and a decrease in cash reserves, it plans further developments in women's health innovations.
Read more →DARE▲ +12.8%on this news
Dar Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menop
Dar Bioscience announced promising results from its Phase 1 / 2 study of DARE-HRT1, an intravaginal ring designed for hormone therapy in menopausal women. The study demonstrated successful delivery of estradiol and progesterone over a 28-day period, showing statistically significant improvements in vasomotor symptoms and vaginal conditions. Dar plans to move forward with a Phase 3 clinical trial to support FDA approval, aiming to position DARE-HRT1 as a groundbreaking option in hormone therapy.
Read more →DAREDar Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a No
Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted Dar Portfolio Accom
Read more →DAREDar Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Sup
Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Therapy for Women with VVA Who Cannot, or Should Not, Ta
Read more →DAREBacterial vaginosis is the most common cause of vaginitis worldwide. The condition results from an overgrowth of bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor and d
Dar Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update September 30, 2022: $40.4 million in cash and cash equivalents Ovaprene : IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implement
Read more →DAREDar Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the pote
Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen
Read more →DAREDar Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene , an Investigational Hormone-Free Monthly Intravaginal Contraceptive Ovaprene has the Potential to be th
Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene , an Investigational Hormone-Free Monthly Intravaginal Contraceptive has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contracep
Read more →DARE▲ +5.4%on this news
Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Dar Bioscience, Inc. ("Dar " or the "Compa
Forward-Looking Statements; Disclaimers 2 This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Dar Bioscience, Inc. ("Dar " or the "Company"). This presentation includes certain information obtaine
Read more →DAREDar Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects
Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Data of Phase 2b RESPOND Study Targeted for 2Q-2023 clinical develo
Read more →DAREDar Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
Bioscience Reports Second Quarter 2022 Financial Results and June 30, 2022: $32.1 million in cash and cash equivalents July 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license agreement with
Read more →DAREDar Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis Dar wil
Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis will receive a $10 million upfront payment from Organon estimated 21
Read more →DAREDar Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to
Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022 to be reconvened solely with respect to Proposal 5 DIEGO, June 24, 2022 (GLOBE NEWSWIRE) - Dar Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced pa
Read more →DARE▲ +9.6%on this news· ran to +20% by day 3
051222 Dar Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update $39.3 million in cash and cash equivalents at
Dar Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update $39.3 million in cash and cash equivalents at March 31, 2022 Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022 Organon exclusive global license agreement for XACIATOTM
Read more →DAREupsets the balance of the natural vaginal microbiome and can lead to symptoms of odor and discharge. In addition to being the most common type of vaginal infection in women of reproductive age and having bothersome sympt
Dar Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update Entered into exclusive global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.
Read more →DARE_________________________________________________________________________________ Organon Media Contacts: Karissa Peer Organon Investor Contacts: Jennifer Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (2
Dar will receive a $10 million upfront payment from Organon. Dar is eligible to receive potential milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales. XACIATO is expected to be available commercially in the U.S. in Q4 2022. Completion o
Read more →DAREDar Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis Six-month priority review granted for DARE-BV1 with PDUFA target action date set f
Dar Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021. NDA supported by positive data from t
Read more →DAREForward-Looking Statements; Disclaimers 2 THIS PRESENTATION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OF DARÉ BIOSCIENCE, INC. ("DARÉ
Forward-Looking Statements; Disclaimers 2 THIS PRESENTATION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OF DAR BIOSCIENCE, INC. ("DAR " OR THE "COMPANY"). THIS PRESENTATION INCLUDES CERTAIN INFORMATION OBTAINE
Read more →DAREDar Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis DARE-BV1 met the primary endpoint of the study and all pre-specified secondar
Dar Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis DARE-BV1 met the primary endpoint of the study and all pre-specified secondary efficacy endpoints demonstrated significantly greater cli
Read more →DAREDar Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
menopause. To learn more about Dar 's full portfolio of women's health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com. Dar may announce material information about its finances, product candidates, clinical trials
Read more →DAREBayer and Dar Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene , an Investigational Hormone-Free, Monthly Contraceptive Dar may be entitled to up to $310 million in co
study costs, then the exclusive license to commercialize Ovaprene in the U.S. will become effective. Dar will also be entitled to receive commercial milestone payments potentially totaling $310 million, in addition to double digit tiered royalties on net sales. "Both Dar and Baye
Read more →DAREDar Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform Contraceptive Program Supported by up to $20.5 Million in Grant Funding
website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its f
Read more →DAREDar Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
Dar Bioscience, Inc. Prices Underwritten Public Offering of Common Stock SAN DIEGO, April 9, 2019 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (NASDAQ:DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 pe
Read more →DAREForward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DAR BIOSCIENCE, INC. ("DAR " OR THE "COMPANY"). THIS PRES
Delivering innovation by daring to be different January 7, 2019 Exhibit 99.1 Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DAR BIOSCIENCE, INC. ("DAR " OR THE "CO
Read more →DAREDar Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis Bacterial vaginosis affects nearly 20 million women in the U.S. every year
Dar Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis Bacterial vaginosis affects nearly 20 million women in the U.S. every year SAN DIEGO, Dec. 6, 2018 (GLOBE NEWSWIRE) Dar Bioscience, Inc. (NA
Read more →DAREDar Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder Sildenafil Cream, 3.6% has the Potential to Receive the First FDA App
Dar Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal SAN DIEGO, Nov. 29, 2018
Read more →DAREDar Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder Sildenafil Cream, 3.6% has the Potential to Receive the Firs
Dar Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO, Nov. 27, 20
Read more →DAREDar Bioscience Provides Business Update and Announces Third Quarter Financial Results San Diego
Dar Bioscience Provides Business Update and Announces Third Quarter Financial Results San Diego, November 13, 2018 (GLOBE NEWSWIRE) Dar Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women s biopharmaceutical company, today provided a business update and announced financial
Read more →DAREGreg Matz Joins Dar Bioscience Board of Directors
Greg Matz Joins Dar Bioscience Board of Directors SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women s biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. Most recently, Mr. M
Read more →DAREDar Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals Intravaginal Ring (IVR) Technology Platform The intravaginal ring technology platform is designed to deliver targeted and
Dar Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals Intravaginal Ring (IVR) Technology Platform The intravaginal ring technology platform is designed to deliver targeted and sustained pharmaceutical formulations addressing unmet n
Read more →DAREJessica Grossman, M.D., Joins Dar Bioscience Board of Directors
Jessica Grossman, M.D., Joins Dar Bioscience Board of Directors SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) Dar Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women s biopharmaceutical company, today announced the appointment of Jessica Grossman, M.D., to its board of directo
Read more →DAREDar Bioscience, Inc. to raise approximately $10.25 million San Diego, CA
Dar Bioscience, Inc. to raise approximately $10.25 million San Diego, CA February 13, 2018 Dar Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its common stock and warrants to purchase
Read more →DAREDar Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder Company enters into license agreement with Strate
Dar Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildena
Read more →DAREForward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DAR BIOSCIENCE, INC. ("dARE" OR THE "COMPANY"). THIS PRES
NASDAQ:DARE January 2018 Delivering innovation by daring to be different biotechnology for women, by women Exhibit 99.1 Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securiti
Read more →DARECerulean and Dar Announce Awards for Dar CEO Ms. Johnson Received Athena Pinnacle Award and Will Receive MOXIE Award WALTHAM, Mass., and
Cerulean and Dar Announce Awards for Dar CEO Ms. Johnson Received Athena Pinnacle Award and Will Receive MOXIE Award WALTHAM, Mass., and SAN DIEGO, California, May 8, 2017 Cerulean Pharma Inc. (NASDAQ:CERU), and Dar Bioscience, Inc., a privately-held, clinical-stage healthcare
Read more →DARETHOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2017 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2017 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Tho
Read more →DARECerulean Pharma and Dar Bioscience Enter into Stock Purchase Agreement Transaction to create NASDAQ-listed company focused on the development and commercialization of women s reproductive health products Sabrina Martucci
Cerulean Pharma and Dar Bioscience Enter into Stock Purchase Agreement Transaction to create NASDAQ-listed company focused on the development and commercialization of women s reproductive health products Sabrina Martucci Johnson to be Named CEO of Combined Company Cerulean an
Read more →DARECerulean and Dar to Host Conference Call on Proposed Transaction on March 23
Cerulean and Dar to Host Conference Call on Proposed Transaction on March 23 CAMBRIDGE, Mass., March 20, 2017 Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Dar Bioscience that the companies will hold a joint conference call to discuss the definitive share pur
Read more →DARECerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update Conference Call Today at 4:30 p.m.
Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update Conference Call Today at 4:30 p.m. ET WALTHAM, Mass., November 3, 2016 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provid
Read more →DARECerulean Announces Technology Platform Collaboration - Collaboration will create nanoparticle-drug conjugates directed at up to five targets - Cerulean will receive an upfront payment of $5 million and is eligible for mi
Cerulean Announces Technology Platform Collaboration - Collaboration will create nanoparticle-drug conjugates directed at up to five targets - Cerulean will receive an upfront payment of $5 million and is eligible for milestone payments plus sales royalties for each target WAL
Read more →DARECOMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the Agreement ), dated as of
COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the Agreement ), dated as of October 14, 2016 by and between CERULEAN PHARMA INC., a Delaware corporation (the Company ), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the Buyer ). Capitaliz
Read more →DARECerulean Announces Reduction in Force
Cerulean Announces Reduction in Force WALTHAM, Mass., August 18, 2016 Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it is reducing its workforce by approximately 48%, to a total of 23 full-time
Read more →DARECerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma CRLX101 plus Avastin Does Not Show Improvement Compared to Standard of Care in this Setting Compa
Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma CRLX101 plus Avastin Does Not Show Improvement Compared to Standard of Care in this Setting Company to Host Conference Call Today at 4:30 pm EDT WALTHAM,
Read more →DARECerulean Reports Second Quarter 2016 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m.
Cerulean Reports Second Quarter 2016 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m. ET WALTHAM, Mass., August 4, 2016 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an
Read more →DARECerulean Reports First Quarter 2016 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m.
Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m. ET WALTHAM, Mass., May 2, 2016 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an upda
Read more →DARECerulean Reports Fourth Quarter 2015 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m.
Cerulean Reports Fourth Quarter 2015 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m. ET WALTHAM, Mass., March 10, 2016 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an
Read more →DARECerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m.
Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results Conference Call Today at 4:30 p.m. CAMBRIDGE, Mass., November 16, 2015 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an
Read more →DARECerulean Appoints Adrian Senderowicz, M.D., as Chief Medical Officer
Cerulean Appoints Adrian Senderowicz, M.D., as Chief Medical Officer CAMBRIDGE, Mass., September 8, 2015 Cerulean Pharma Inc. (NASDAQ:CERU), a leader in Dynamic Tumor Targeting , today announced the appointment of Adrian Senderowicz, M.D., as Senior Vice President & Chief Medic
Read more →DARECerulean Reports Second Quarter 2015 Corporate Highlights and Financial Results Strengthened Balance Sheet with Underwritten Public Offering of Common Stock Conference Call Today at 4:30 pm
Cerulean Reports Second Quarter 2015 Corporate Highlights and Financial Results Strengthened Balance Sheet with Underwritten Public Offering of Common Stock Conference Call Today at 4:30 pm CAMBRIDGE, Mass., August 6, 2015 - Cerulean Pharma Inc. (Nasdaq: CERU) today provided a
Read more →DARECerulean Appoints Interim Chief Financial Officer
Cerulean Appoints Interim Chief Financial Officer CAMBRIDGE, Mass., May 27, 2015 Cerulean Pharma Inc. (Nasdaq: CERU) today announced the appointment of Gregg Beloff, J.D., M.B.A., as Interim Chief Financial Officer. Gregg brings extensive financial experience and leadership to
Read more →DARECerulean Reports First Quarter 2015 Corporate Highlights and Financial Results Phase 1b/2 trial of CRLX101 in combination with Avastin in metastatic renal cell carcinoma achieved primary endpoint CRLX101 in combination w
Cerulean Reports First Quarter 2015 Corporate Highlights and Financial Results Phase 1b/2 trial of CRLX101 in combination with Avastin in metastatic renal cell carcinoma achieved primary endpoint CRLX101 in combination with Avastin granted Fast Track designation in metastatic r
Read more →DARECerulean Appoints Chris Guiffre President & Chief Executive Officer Paul Friedman to continue to serve as Executive Chairman and Bill Rastetter to continue to serve as Lead Independent Director
Cerulean Appoints Chris Guiffre President & Chief Executive Officer Paul Friedman to continue to serve as Executive Chairman and Bill Rastetter to continue to serve as Lead Independent Director CAMBRIDGE, Mass., March 20, 2015 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dy
Read more →DARECerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results Phase 1b/2 trial of CRLX101 in renal cell carcinoma achieves primary endpoint Closed debt facility for up to $26.0 million with Hercules Tec
Cerulean Reports Fourth Quarter 2014 Corporate Highlights and Financial Results Phase 1b/2 trial of CRLX101 in renal cell carcinoma achieves primary endpoint Closed debt facility for up to $26.0 million with Hercules Technology Growth Capital in first quarter CAMBRIDGE, Mass.,
Read more →DARECerulean Secures Debt Facility from Hercules Technology Growth Capital of Up to $26.0 Million
Cerulean Secures Debt Facility from Hercules Technology Growth Capital of Up to $26.0 Million CAMBRIDGE, Mass., January 8, 2015 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting , today announced that it has entered into a loan and security agreement with
Read more →DARECerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results
Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results CAMBRIDGE, Mass., November 13, 2014 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting , today provided an update on corporate activities during the quarter ended September 30,
Read more →DARECerulean Reports Second Quarter 2014 Corporate Highlights and Financial Results
Cerulean Reports Second Quarter 2014 Corporate Highlights and Financial Results CAMBRIDGE, Mass. August 12, 2014 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting , today provided an update on corporate activities during the quarter ended June 30, 2014.
Read more →DARECerulean Reports First Quarter 2014 Corporate Highlights and Financial Results
Cerulean Reports First Quarter 2014 Corporate Highlights and Financial Results CAMBRIDGE, Mass. May 27, 2014 Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting , today provided an update on corporate activities during the quarter ended March 31, 2014. Ce
Read more →Competitive Position
How DARE ranks across every disease it competes inCompetitive Position is a premium feature
See how DARE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial